Labcorp is scheduled to report its second-quarter 2026 results on July 30 before the market opens. The Zacks Consensus Estimate for revenues is $3.72 billion, indicating a 5.4% increase from the year-ago period, while the consensus earnings per share estimate of $4.79 suggests a 10.1% improvement. The company has an Earnings ESP of +0.71% and a Zacks Rank of 2, which according to Zacks Investment Research signals a higher likelihood of an earnings beat. Key drivers for the quarter include strong organic growth in Diagnostics Laboratories, supported by health system partnerships and acquisitions, as well as an expanding specialty testing portfolio in areas such as oncology and neurology.
Alcon AG
Henry Schein IncLaboratory Corporation of America HoldingsLabcorp is the subject of the article; expected earnings beat and revenue growth are positive for the stock.
CVS Health Corp